TRT for Fatigue: Does Testosterone Replacement Actually Work?

Note on this draft: this article is pending qualified medical review. Several precise figures in earlier versions of this page could not be traced to a verifiable primary source and have been removed or narrowed below. Numbers that remain are flagged where independent verification against the original publication is still needed.

Testosterone replacement therapy (TRT) refers to prescription testosterone, given as intramuscular or subcutaneous injections (testosterone cypionate or enanthate), transdermal gels or patches, nasal gel, or subcutaneous pellets, used to restore serum testosterone in men with a laboratory-confirmed deficiency. It is not the same as over-the-counter "testosterone boosters," compounded troches sold outside FDA-regulated pathways, or anabolic steroid use for performance purposes.

The direct answer

TRT reliably reduces fatigue, low libido, and related symptoms in men who have biochemically confirmed hypogonadism, meaning low morning testosterone on repeat testing plus compatible symptoms. It does not reliably help fatigue in men whose testosterone is in the normal range, and giving testosterone to a eugonadal man for tiredness is not an FDA-approved use and is not supported by the trial evidence. The clinically important question is not "does testosterone fight fatigue" but "has this man's fatigue actually been shown to come from testosterone deficiency, and has anything else been ruled out first."

Why low testosterone causes fatigue, and why it often doesn't

Testosterone supports several systems that affect how tired a person feels day to day: red blood cell production (via effects on erythropoietin sensitivity), skeletal muscle maintenance, and signaling in brain pathways related to motivation and mood. When testosterone drops well below the normal range, men commonly describe a flat, unmotivated tiredness rather than simple sleepiness.

That said, fatigue is a nonspecific symptom. Thyroid disease, obstructive sleep apnea, iron deficiency, depression, poor sleep, and chronic illness all produce very similar complaints, and several of these are more common than confirmed hypogonadism. A responsible workup checks for these before attributing fatigue to testosterone, because starting TRT does not fix a thyroid or sleep problem and can delay the correct diagnosis.

The American Urological Association's 2018 testosterone deficiency guideline and the Endocrine Society's 2018 clinical practice guideline on male hypogonadism both describe testosterone deficiency as a real, treatable condition that can contribute to fatigue, low libido, and reduced quality of life, but both guidelines also emphasize that treatment should follow, not precede, a confirmed diagnosis. Readers and editors should verify the exact guideline language against the current published versions before quoting it directly, since guideline wording is periodically updated.

Primary vs. secondary hypogonadism: why the cause changes the treatment

Low testosterone has two broad origins, and the distinction changes what should happen next.

Primary hypogonadism means the testes themselves are underproducing testosterone despite adequate signaling from the pituitary. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are elevated because the pituitary is trying to compensate. Causes include Klinefelter syndrome, prior chemotherapy or radiation, testicular injury, and orchitis. TRT is the standard approach here because the problem is at the level of the testes.

Secondary hypogonadism means testosterone is low but LH and FSH are low or inappropriately normal, indicating the signal from the pituitary or hypothalamus is inadequate. Causes include obesity-related suppression, opioid use, elevated prolactin, and pituitary tumors. In these cases, medications that stimulate the body's own testosterone production, such as clomiphene citrate or human chorionic gonadotropin (hCG), are sometimes used instead of TRT, particularly when a man wants to preserve fertility. TRT suppresses LH and FSH further and shuts down sperm production, an effect that clomiphene and hCG largely avoid.

Because a pituitary tumor is one possible cause of secondary hypogonadism, measuring LH, FSH, and prolactin before starting any treatment is standard practice, and an elevated prolactin typically prompts pituitary imaging.

What the trial evidence actually shows

The strongest evidence in this area comes from the NIH-funded Testosterone Trials, a set of coordinated placebo-controlled trials in older men (roughly 65 and older) with confirmed low testosterone. Across these trials, testosterone treatment produced measurable improvements in sexual function and some measures of physical function and mood compared with placebo, over roughly one year of treatment. The exact effect sizes reported in the published papers should be checked directly before being cited with precision, since this draft could not independently confirm each numeric result against a verified source.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was a large (thousands of participants), placebo-controlled cardiovascular safety study of testosterone therapy in middle-aged and older hypogonadal men with elevated cardiovascular risk. Its primary finding was that testosterone therapy did not increase major adverse cardiac events compared with placebo over roughly three years of follow-up, which addressed a long-standing safety concern about TRT and heart disease. Energy and fatigue were secondary outcomes in that trial rather than the primary endpoint, and any specific percentage improvement attributed to it should be verified against the published paper before use.

Several meta-analyses and systematic reviews of testosterone therapy have reported improvements in sexual function, mood, and body composition in hypogonadal men, generally with larger effects in men who started with more severely low testosterone. Evidence on bone density and long-term cardiovascular outcomes beyond TRAVERSE remains less mature, and the Endocrine Society and Cochrane reviews in this space have both noted that longer-term data are still limited.

What this means in practice: the trial evidence supports treating confirmed, biochemically documented hypogonadism, with meaningful but not universal improvement in fatigue and sexual symptoms over weeks to months. It does not support testing testosterone once, seeing a borderline or normal number, and treating fatigue anyway. It also does not settle every long-term safety question, particularly around bone and long-term cardiovascular risk beyond the TRAVERSE population and follow-up window.

Andropause and age-related decline: what's established and what isn't

Total testosterone declines gradually with age in most men, and a portion of aging men develop a recognizable pattern of low testosterone plus symptoms sometimes called late-onset hypogonadism. The European Male Aging Study, a large observational cohort, is the most cited source describing this pattern and its associated symptom cluster, which typically centers on sexual symptoms (reduced morning erections, reduced sexual thoughts, low libido) alongside fatigue. Editors should confirm the specific prevalence figures from that cohort against the original publication before repeating them as precise percentages, since exact numbers vary across published analyses of the same dataset.

What is established: testosterone falls with age on average, and a meaningful minority of older men develop symptoms consistent with hypogonadism. What is plausible but less firmly established: the exact serum threshold at which fatigue specifically (as opposed to sexual symptoms) becomes attributable to low testosterone, since fatigue is also common in aging men for unrelated reasons. What is not established: that testosterone supplementation is an appropriate or effective treatment for age-related tiredness in men whose testosterone is within the normal reference range.

TRT for low libido

Libido is the symptom most consistently and clearly improved by TRT in confirmed hypogonadal men, more so than fatigue alone. Free testosterone, the fraction of testosterone not bound to sex hormone binding globulin (SHBG), tracks libido more closely than total testosterone, which is why free or calculated free testosterone is worth checking in men with high SHBG (common with aging and obesity) whose total testosterone looks borderline.

Sexual desire improvements in trials have generally taken several weeks to appear rather than being immediate, and estrogen balance also matters: testosterone is partly converted to estradiol in the body, and estradiol contributes to libido as well, so aggressively suppressing estradiol with an aromatase inhibitor can backfire.

TRT for erectile dysfunction

Erectile dysfunction (ED) has multiple contributing causes, including vascular disease, diabetes, medication side effects, psychological factors, and low testosterone. In men whose ED is at least partly driven by confirmed hypogonadism, testosterone therapy improves erectile function in a meaningful proportion of cases, though the exact proportion reported across studies varies and a specific percentage should not be treated as a fixed clinical statistic without checking the source study population and methods.

When TRT alone is not enough, adding a PDE5 inhibitor (sildenafil or tadalafil) is a standard combination approach supported by clinical guidelines for men with both documented low testosterone and residual ED. TRT is not an approved or evidence-supported treatment for ED in men with normal testosterone levels, and no FDA-approved testosterone product is indicated for ED in eugonadal men, consistent with FDA safety guidance on testosterone products; confirm current label language before citing, as safety communications and labeling can be updated.

How TRT is given

FDA-approved testosterone formulations differ in convenience, cost, and side effect profile:

• Injectable testosterone cypionate or enanthate (intramuscular or subcutaneous, typically weekly or split into twice-weekly doses): the lowest-cost option with well-established pharmacokinetics.
• Transdermal gels and patches applied daily: convenient, but carry a real risk of skin transference to partners or children if application sites are not covered and hands are not washed.
• Long-acting injectable testosterone undecanoate, given in-office on an extended schedule: requires a post-injection observation period in the clinic because of a rare risk of pulmonary oil microembolism, as noted in FDA labeling.
• Nasal gel, applied multiple times daily: avoids skin transference and may cause less suppression of the body's own hormone signaling than other forms.
• Subcutaneous pellets, implanted every few months: convenient dosing interval, but adjusting the dose requires a new procedure rather than a simple prescription change.

The right choice depends on cost, needle tolerance, household exposure risk (children or pregnant partners), and how a man tolerates fluctuating versus steady serum levels.

Monitoring once TRT starts

TRT is not a start-once, forget-it therapy. Standard monitoring, consistent with Endocrine Society guidance, includes checking testosterone, hematocrit, and PSA at intervals in the first year and then periodically thereafter. The core things monitoring is designed to catch:

• Elevated hematocrit (polycythemia), which raises the risk of blood clots and is a reason to reduce dose or pause treatment. This is a well-documented, dose-related side effect of testosterone therapy.
• A significant PSA rise, which prompts urology evaluation rather than automatic discontinuation, since TRT itself has not been shown in large trials such as TRAVERSE to increase prostate cancer incidence, though PSA surveillance remains standard practice.
• Bone density, particularly in men with osteopenia or a fracture history, since testosterone affects bone turnover over the course of a year or more.
• Fertility, since TRT suppresses the body's own LH and FSH and, with it, sperm production. Men who want to father children in the near term should discuss clomiphene or hCG, or sperm banking, before starting TRT rather than after.

A realistic timeline: sleep and mood-related symptoms are often the first to shift, over the first several weeks. Libido and erectile changes tend to follow over one to two months. Body composition changes take a few months to become measurable, and bone density changes take a year or more to show up on a scan. These are general patterns from the literature, not a guarantee for any individual.

What you need before TRT is considered

Fatigue by itself is not a diagnosis. A reasonable pre-TRT workup, consistent with major society guidance, includes:

• Two separate morning, fasting total testosterone measurements (testosterone follows a daily rhythm and is highest in the morning; an afternoon draw can look falsely normal).
• LH, FSH, and prolactin, to distinguish primary from secondary hypogonadism and screen for a pituitary cause.
• Free or calculated free testosterone plus SHBG and albumin, particularly relevant in men with obesity or older age where SHBG shifts total testosterone results.
• A basic evaluation for other fatigue causes: thyroid-stimulating hormone (TSH), a complete blood count and ferritin (for anemia or iron deficiency), and a screen for obstructive sleep apnea symptoms in men who are overweight or snore heavily.
• PSA in men over 40, as a baseline before treatment.

Evidence boundary: what's established, what's plausible, what isn't

Established: Testosterone deficiency, confirmed by repeat morning labs plus symptoms, is a recognized medical condition. TRT improves libido and sexual function in confirmed hypogonadal men in randomized trials. The TRAVERSE trial found no increase in major cardiac events from TRT in a high-risk population over roughly three years. Hematocrit elevation is a real, monitorable side effect.

Plausible but not firmly proven: That TRT reliably improves fatigue as a standalone symptom independent of libido and mood improvements, at a magnitude and timeline that generalizes across all hypogonadal men. That specific serum thresholds (like a single free testosterone cutoff) predict who will respond to treatment.

Not established: That TRT improves fatigue, energy, or ED in men with testosterone in the normal reference range. That long-term cardiovascular and bone safety beyond the TRAVERSE trial's population and follow-up window is fully settled. That any over-the-counter "testosterone support" supplement produces effects comparable to prescription TRT.

Decision framework: should fatigue prompt a TRT conversation?

Use this as a starting checklist for a conversation with a clinician, not as a self-diagnosis tool.

Failure modes to watch for: starting TRT from a single, non-fasting, or afternoon testosterone level; treating fatigue with TRT while skipping thyroid and sleep apnea screening; using TRT in a man who wants to conceive soon without discussing fertility-preserving alternatives; continuing TRT despite rising hematocrit or PSA without follow-up; and expecting fatigue improvement on a timeline of days rather than weeks to months.

When to seek care urgently rather than start TRT

Fatigue accompanied by chest pain, shortness of breath, fainting, sudden vision changes, severe headache, or signs of a blood clot (leg swelling, calf pain) needs urgent medical evaluation, not a testosterone conversation. Men on TRT who develop these symptoms, or a hematocrit significantly above the monitored threshold, should contact their prescribing clinician promptly rather than waiting for a routine follow-up.